Product Details
| Product Name:
AMG 487 |
CAS No.:
473719-41-4 |
| Purity:
99.82% |
Supply Ability:
10g |
| Release date:
2026/04/21 |
Product Introduction
Bioactivity
| Name | AMG 487 |
| Description | AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively. |
| In vitro | AMG487 is a small molecular weight antagonist of CXCR3. 66.1 tumor cells were pretreated with AMG487 prior to i.v. injection into immune-competent female mice. Antagonism of CXCR3 on 66.1 tumor cells inhibited experimental lung metastasis, and this antimetastatic activity was compromised in mice depleted of natural killer cells. Systemic administration of AMG487 also inhibited experimental lung metastasis. In contrast to the antimetastatic effect of AMG487, local growth of 66.1 mammary tumors was not affected by receptor antagonism. Murine mammary tumor cells express CXCR3 which facilitates the development of lung metastases.Indicate for the first time that a small molecular weight antagonist of CXCR3 has the potential to inhibit tumor metastasis[2].
|
| In vivo | AMG487, a small molecular weight antagonist. In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited the implantation and the growth of human and mouse CRC cells within lung without affecting that in the liver. In addition, we measured increased levels of CXCR3 and ligands expression within lung nodules compared with liver tumours. Activation of CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models[3].
|
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.31 mM), Sonication is recommended.
DMSO : 41 mg/mL (67.93 mM), Sonication is recommended.
|
| Keywords | receptor | Metastatic | metastasis | Inhibitor | inhibit | CXCR3 | CXCR | CXCL11 | CXCL10 | CXC chemokine receptors | colon | chemokine | cancer | Breast | AMG-487 | AMG487 | AMG 487 | 125I-ITAC-CXCR3 | 125I-IP10-CXCR3 |
| Inhibitors Related | AZD8309 | rac-NBI-74330 | Tannic acid | Artemotil | CXCR2-IN-1 | Kynurenic acid | Soquelitinib | Plerixafor octahydrochloride | Tanimilast | 3-Indoleglyoxylic acid | Nicotinamide N-oxide | CXCL-CXCR1/2-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Autophagy Compound Library | Chemokine Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$38.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
|
|
|
VIP3Y
|
HR Biotechnology Co.,Ltd
|
2026-05-03 |
|
|
$46.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-21 |
|
|
$48.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-04-28 |
United States